Staphylococcal Sepsis Prevention Study
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis
Protocol ID
09-10-126
Protocol Description
Premature babies have a higher risk of developing sepsis while in the hospital. Sepsis is the body's response to an infection in the blood caused by bacteria. The purpose of this study is to show whether an experimental drug, pagibaximab, is safe and if it can prevent sepsis in premature babies.
Eligibility Criteria
Premature infants
Primary Investigator(s)
- Kavita Kasat, MD
- Regina Spinazzola-Kinney, MD
Contact Information
For Dr. Kasat:
Barbara Wilkens, RN (718) 470-3568 bwilkens@lij.edu
>
For Dr. Spinazzola-Kinney:>
Debra Potak, RN>
(516) 562-2205>
dpotak@nshs.edu
Barbara Wilkens, RN (718) 470-3568 bwilkens@lij.edu
>
For Dr. Spinazzola-Kinney:>
Debra Potak, RN>
(516) 562-2205>
dpotak@nshs.edu